Clinical trials: Disorder, Mood
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Safety and Tolerability of Zelquistinel in Normal Human Volunteers
To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers
- Trial name
- NCT04981561
- Testing
- zelquistinel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
- Trial name
- NCT00358631
- Testing
- SSR149415
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Sanofi
Bipolar Disorder
Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during a long-term open label study in children and adolescents (ages 10-17) with Bipolar I Disorder (Manic or Mixed).
- Trial name
- NCT01124877
- Testing
- ziprasidone oral capsules
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved…
- Trial name
- STEP-D222 (NCT01052077)
- Testing
- OPC-34712, ADT
- Where
- 43 sites in United States
- Volunteers
- 773 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients
The purpose of this study is to determine the initial (after 1-week of maintenance dosing) and extended (after 3-weeks of maintenance dosing) effect of topiramate, at doses up to 600 mg/day, on the steady-state pharmacokinetics…
- Trial name
- NCT00986128
- Testing
- topiramate
- Volunteers
- 32 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
A Study of Intermittent Doses of CERC-301 in MDD
There is a significant unmet medical need for rapidly acting treatment of subjects with severe major depressive disorder (MDD) who have not adequately responded to antidepressant therapy.
- Trial name
- NCT02459236
- Testing
- CERC-301
- Where
- 13 sites in United States
- Volunteers
- 115 people
- Sponsor
- Avalo Therapeutics, Inc.
Bipolar Disorder
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
The primary purpose of this study is to evaluate the safety and efficacy of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Trial name
- NCT00035230
- Testing
- Topiramate
- Volunteers
- 338 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Depressive Disorder, Major
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of…
- Trial name
- NCT04984512
- Testing
- Mitizodone Phosphate tablets
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Major Depressive Disorder (MDD)
A Study of HS-10353 in Adult Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of continuous oral administration of HS-10353 in Chinese adults with depression.HS-10353 is a new generation of…
- Trial name
- NCT05938179
- Testing
- HS-10353 30mg oral capsules, HS-10353 50mg oral capsules
- Volunteers
- 144 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Menopause, Menopausal Symptoms
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
This study evaluates the effects of Primal Harvest's Primal Meno+ supplement on symptoms of menopause and overall well-being in females aged 40-60 who are currently menopausal and experiencing at least two menopausal symptoms.
- Conditions
- Menopause, Menopausal Symptoms, Hot Flashes, Night Sweats
- Trial name
- NCT07903480
- Testing
- Primal Meno+ Supplement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Primal Harvest, LLC
Major Depressive Disorder
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Trial name
- APPROACH (NCT06564818)
- Testing
- CYB003, Psychological Support
- Where
- 45 sites in United States
- Volunteers
- 223 people
- Sponsor
- Cybin IRL Limited
Major Depressive Disorder
A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of 10, 20, 40 and 60 mg oral PRAX-114 compared to placebo in the treatment of adults with MDD.
- Trial name
- NCT04969510
- Testing
- 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114
- Where
- 24 sites in United States, Australia
- Volunteers
- 110 people
- Sponsor
- Praxis Precision Medicines
Depressive Disorder, Major
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
To determine if the NMDA antagonist, CP-101,606, is effective for depression
- Trial name
- NCT00163059
- Testing
- NMDA Antagonist, CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder
Bipolar disorder affects 2.4 million adults in the USA between the ages of 18-65 and has considerable economic impact on our society.
- Trial name
- NCT00106405
- Testing
- Memantine HCl
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 /…
- Trial name
- NCT00761306
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 74 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder
A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects
The study was designed to assess the steady-state pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release tablet formulation (25 mg) in healthy Chinese subjects.
- Trial name
- NCT00406432
- Testing
- Paroxetine Controlled Release Tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for participants with major depressive disorder (MDD), who were identified as partial responders to an adequate course…
- Trial name
- NCT00840034
- Testing
- LY2216684
- Where
- 24 sites in United States
- Volunteers
- 227 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.